Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
Most people think drug exclusivity is a simple clock: 20 years from filing, then the floodgates open. In reality, the timeline is more like a chess matchplayed across patents, regulat…

Pharma mega-deals dont get done on vibes. They get done on exclusivity.
If youve ever wondered why two companies can look equally promising on paperyet one commands a premium valuation while the other gets treated like a nice-to-havethe answer is often…

Patent cliffs aren’t just a legal event—they’re a pricing event.
When a blockbuster’s exclusivity window ends, the market doesn’t wait for your forecast model to catch up. Generic and biosimilar entrants arrive, payers reprice, formularies shift, and…

Post-approval is where many drug strategies quietly fail.
Youve secured approvalcongrats. But the real test begins the day the label goes live. In the months and years after launch, your product is exposed to a different kind of risk: regulatory challe…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…

Pharma patent strategy is supposed to be about protecting exclusivity.
But in 2026, protecting often means something more specific: defending your position without triggering the very lawsuits youre trying to avoid.
That tensionbetween aggressive enfor…

The Composition of Matter Cliff Is Here. The Playbook Is Already Written.
If youve worked in pharma long enough, youve heard the phrase patent cliff so many times it starts to sound like weatherinevitable, cyclical, and mostly out of your control.
But …

Pharmas patent cliff isnt just a cliff. Its a math problemand a legal one.
For years, investors have focused on the headline expiration dates: the moment a blockbusters primary patent term ends, generics rush in, and revenue curves bend downward. But t…

The Patent Dance Is Not a DanceIts a Deadline. Heres How Biosimilar Developers Win (or Lose) Before Court Ever Opens.
If youve ever watched a biosimilar case unfold, youve probably noticed the same pattern: the real fight doesnt start in the courtroom….

Drug patent cliffs are no longer a surprisetheyre a forecast.
For years, pharma strategy teams have treated patent expiration like weather: you can track it, but you cant control itand you definitely cant predict it with certainty until its already on …